title: Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
abstract: During 2007-2008, 1,036 gram-negative bacilli were isolated from patients with complicated intra-abdominal infections in the United States. Against members of the family Enterobacteriaceae, the most active agents in vitro were ertapenem, imipenem, and amikacin, while the least active agent was ampicillin-sulbactam. Ertapenem and imipenem were active against all extended-spectrum-beta-lactamase (ESBL)-positive Escherichia coli. Antimicrobial resistance in gram-negative bacilli isolated from patients with complicated intra-abdominal infections in the United States continues to increase.
authors.affiliation: International Health Management Associates, 2122 Palmer Drive, Schaumburg, IL 60173, USA. dhoban@ihmainc.com
authors.forename: Daryl J
authors.initials: DJ
authors.lastname: Hoban
authors.forename: Samuel K
authors.initials: SK
authors.lastname: Bouchillon
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hawser
authors.forename: Robert E
authors.initials: RE
authors.lastname: Badal
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Labombardi
authors.forename: Joseph
authors.initials: J
authors.lastname: DiPersio
mesh_terms: D000005:Abdomen / Q000382:microbiology*; D000583:Amikacin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000472:pathogenicity; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects / Q000472:pathogenicity; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000472:pathogenicity*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D047090:beta-Lactams / Q000494:pharmacology
chemical_list: D047090:beta-Lactams; D015378:Imipenem; D000583:Amikacin; D000077727:Ertapenem
references.citation: J Antimicrob Chemother. 2005 Jun;55(6):965-73
references.pmid: 15849262
references.citation: Int J Antimicrob Agents. 2009 Dec;34(6):585-8
references.pmid: 19748234
references.citation: Antimicrob Agents Chemother. 2007 Nov;51(11):4015-21
references.pmid: 17724160
references.citation: Diagn Microbiol Infect Dis. 2010 Jan;66(1):78-86
references.pmid: 19733993
references.citation: Clin Microbiol Infect. 2008 Jan;14 Suppl 1:111-6
references.pmid: 18154534
references.citation: Clin Infect Dis. 2003 Oct 15;37(8):997-1005
references.pmid: 14523762
references.citation: J Antimicrob Chemother. 2009 Apr;63(4):785-94
references.pmid: 19196742
references.citation: J Antimicrob Chemother. 2006 Jul;58(1):205-10
references.pmid: 16717055
references.citation: Diagn Microbiol Infect Dis. 2005 Aug;52(4):323-9
references.pmid: 16165001
references.citation: Antimicrob Agents Chemother. 2009 Aug;53(8):3280-4
references.pmid: 19506060
references.citation: Surg Infect (Larchmt). 2009 Apr;10(2):99-104
references.pmid: 18831681